High levels of TRAF2, an E3 ligase that plays a role in NF-κB signaling, have been found to be correlated with less favorable outcomes in GBM patients [97], potentially due to the promotion of tumor cell migration [98,99], radio-resistance [100], and stemness of GSCs and GBM initiating cells (GICs) [101]. This evidence concerns the gene NFKB1 and glioblastoma.